ObjectiveTo investigate the clinical therapeutic effect of gemcitabine hydrochloride combined with stereotactic radiotherapy for locally advanced pancreatic cancer. MethodsA total of 122 previously untreated patients with locally advanced pancreatic cancer who were not able to undergo surgical resection and were admitted to Fuzhou General Hospital from June 2008 to June 2013 were selected, and according to the therapies, they were divided into the group with a combination of gemcitabine hydrochloride and stereotactic radiotherapy (group A, n=56) and the group with gemcitabine therapy alone (group B, n=66). The changes in condition, toxic and side effects, and death time were recorded. The chi-square test was applied for comparison between groups, and the Kaplan-Meier method was applied for plotting survival curves. ResultsThere was a significant difference in response rate between group A and group B ［67.8% (38/56) vs 227% (15/66), χ2=25.11, P＜0.01］; the effective pain-relieving rate showed a significant difference between group A and group B (95.8% vs 77.2%, χ2=7.39, P＜0.01); there were significant differences in 1-year survival rate, 2-year survival rate, and median survival time between the two groups ［58.9% (33/56) vs 31.8% (21/66), χ2=9.03, P＜0.01; 28.6% (16/56) vs 106% (7/66), χ2=6.39, P＜0.01; 12.8 months vs 7.9 months; χ2=15.51, P＜0.01］. ConclusionGemcitabine hydrochloride combined with stereotactic radiotherapy has good short- and long-term efficacy, and toxic and side effects are tolerable.

Objective To investigate the role of miR-374-5p in regulating mesenchymal stem cells ( MSCs) derived from gastric tissues to promote the proliferation and migration of gastric cancer cells in vitro. Methods The gastric cancer-mesenchymal stem cells ( GC-MSC) and the matched paracancerous tissue of gastric cancer derived normal mesenchymal stem cells ( GCN-MSC) were isolated and cultured in vitro. Gastric cancer cells were treated with the culture supernatants of GCN-MSC and GC-MSC respectively in vitro. The proliferation ability of gastric cancer cells was detected by plate clone test and the migration ability was detected by scratch test. MiR-374-5p mimics were used to over-express miR-374-5p in GC-MSC and GCN-MSC and MiR-374-5p inhibitor was used to inhibit its expression level. The culture supernatant of MSCs after transfection was collected and gastric cancer cells were treated in vitro. The changes of proliferation and migration ability of gastric cancer cells were observed. Results The number of single cell colonies formed in GC-MSC culture supernatant group (112±7) was more than that of GCN-MSC group (48±6) and the distance between the cells (6.5±0.5 cm) was less than that of GCN-MSC group (15±1) cm, by which the proliferation and migration of gastric cancer cells were significantly promoted (t=12.02, P<0.01 and t=13.17, P<0.01,respectively). Following miR-374-5p overexpressing in the culture supernatant of GCN-MSC,the number of single cell colonies increased (115±12.1) and space between cells reduced (7.83±1.08 cm), by which the proliferation ( t=9.31, P<0.01) and migration ( t=4.88, P<0.01) of gastric cancer were also promoted. The miR-374-5p inhibitor reversed the GC-MSC-induced ability of proliferation and migration of gastric cancer ( t=5.47,P<0.01 and t=4.95,P<0.01) . In the inhibitor group the number of single cell colonies decreased (60±10.2) and the space between cells increased (12.17±1.47cm) following treating by the culture supernatant. Conclusion MiR-374-5p should be an important molecule that regulates MSC in tumoral microenvironment to promote the proliferation and migration of gastric cancer and may become a prospective target for diagnosis and treatment of gastric cancer.

Since the National Health Commission launched the pilot work of " Internet+ nursing service" in 2019, medical institutions at all levels in China keep innovating their nursing service models to provide targeted high-quality care for discharged patients or special groups suffering from diseases and poor mobility. In April 2021, a tertiary hospital in Qingdao carried out the " Internet+ " whole course management practice with specialized nurses as the main service subjects, which center on discharged patients as the main service objects. By estabusing a management team and the construction of " Internet+ " information exchange platform, the hospital implemented the whole course of disease management process including patients′ pre-hospital management, in-hospital estimate, and post-hospital follow-up rehabilitation, to provide specialized nursing services such as PICC dressing change care, stoma care, and mother and infant care for patients at home. By February 2022, the " Internet+ " whole course management service had expanded to 50 kilometers away from hospital, with a total of 1 181 specialized nursing services. This management highlighted the characteristics of specialized nursing services in tertiary hospitals, accurately matched the needs of patients, reflected the concept of holistic care, and provided references for the rapid promotion of the development of " Internet+ nursing service" in China.

Liver cancer is one of the most common cancers in China. In recent years, liver cancer tends to be treated with comprehensive therapies, including surgery, ablation, interventional embolization, radiotherapy, chemotherapy, targeted therapy, immunotherapy, and liver transplantation. At present, the low surgical resectionrate is one of the main factors affecting the prognosis of liver cancer patients. Preoperative neoadjuvant therapy or conversion therapy for liver cancer can maximize the rate of surgical resection and improve the prognosis. With the rapid development of radiotherapy and immunotherapy in the comprehensive treatment of liver cancer, it has been gradually confirmed that the unique effects of preoperative radiotherapy and immune therapy for liver cancer can improve the prognosis of the patients. Therefore, this paper reviewed the research progress in the preoperative radiotherapy and immunotherapy for liver cancer by searching relevant literature and reports at home and abroad.

Objective:To investigate the clinical effectiveness of vertebroplasty for osteoporotic vertebral compression fractures in the elderly aged 90 years and over.Methods:Clinical data of 64 elderly patients aged 90 years and over who had undergone percutaneous vertebroplasty for vertebral compression fractures between January 2015 and January 2021 were retrospectively analyzed.Changes in preoperative and postoperative pain, intraoperative bone cement leakage, postoperative pneumonia, bedsores, urinary tract infections, lower extremity venous thrombosis and changes in preoperative and postoperative physical mobility were evaluated.Pain scores, physical mobility scores, bone cement extravasation and complications such as re-fractures of the vertebral body, postoperative pneumonia, bedsores, urinary tract infections and thrombosis were recorded before surgery, 3 and 30 days after surgery.Results:The visual analogue scale(VAS)scores of 64 patients before surgery, 3 and 30 days after the procedure were 8.34±1.12, 2.17±1.45 and 1.83±1.15, retrospectively( F=540.876, P<0.01). The physical mobility scores before surgery, 3 and 30 days after the procedure were 2.83±0.94, 1.59±0.70 and 1.39±0.60, retrospectively( F=65.492, P<0.01). There were 18 cases(28.13%)of bone cement leakage during surgery, 4 cases(6.25%)of pneumonia within 30 days after surgery, 9 cases(14.06%)of urinary tract infections, 3 cases(4.69%)of lower extremity venous thrombosis, 1 case(1.56%)of bedsores, and 2 cases(3.13%)of vertebral re-fractures after surgery.No patient died during the 30-day follow-up. Conclusions:Percutaneous vertebroplasty can reduce pain and improve physical mobility and is an effective and safe minimally invasive treatment for elderly patients with spinal compression fractures aged 90 years and over.

In China, the survival rate of liver cancer remains low while the mortality rate is high. Effectively reducing the burden of liver cancer is still a major challenge in the field of public health and chronic disease prevention in the Chinese population. Optimizing screening strategies for liver cancer remains a profound approach to secondary prevention worthy of continuous explora-tion. This guideline was commissioned by the Bureau of Disease Control and Prevention of the National Health Commission. The National Cancer Center of China initiated the guideline develop-ment and convened a multidisciplinary expert panel and working group. Following the World Health Organization Handbook for Guideline Development, this guideline integrated the most up-to-date evidence of liver cancer screening, China′s national conditions, and existing practical experience in liver cancer screening. Evidence-based recommendations on the target population, screening technologies, surveillance strategies, and other key points across the process of liver cancer screening and surveillance management were provided. This guideline would help to standardize the practice of liver cancer screening in China.

In China, the survival rate of liver cancer remains low while the mortality rate is high. Effectively reducing the burden of liver cancer is still a major challenge in the field of public health and chronic disease prevention in the Chinese population. Optimizing screening strategies for liver cancer remains a profound approach to secondary prevention worthy of continuous exploration. To address this pressing issue, the Bureau of Disease Control and Prevention of the National Health Commission commissioned this guideline. The National Cancer Center of China initiated the guideline development and convened a multidisciplinary expert panel and working groups. Following the World Health Organization Handbook for Guideline Development, this guideline integrated the most up-to-date evidence of liver cancer screening, China's national conditions, and existing practical experience in liver cancer screening. Evidence-based recommendations on the target population, screening technologies, surveillance strategies, and other key points across the process of liver cancer screening and surveillance management were provided. This guideline would help standardize the practice of liver cancer screening in China.